Polypharmacy and Medication Regimen Complexity as Risk Factors for Hospitalization Among Residents of Long-Term Care Facilities: A Prospective Cohort Study

2016 ◽  
Vol 17 (11) ◽  
pp. 1067.e1-1067.e6 ◽  
Author(s):  
Samanta Lalic ◽  
Janet K. Sluggett ◽  
Jenni Ilomäki ◽  
Barbara C. Wimmer ◽  
Edwin C.K. Tan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cohort Study ◽  
Prospective Cohort ◽  
Long Term Care ◽  
Medication Regimen ◽  
Term Care ◽  
Medication Regimen Complexity ◽  
Regimen Complexity ◽  
Care Facilities

Factors associated with medication regimen complexity in residents of long-term care facilities

2015 ◽  
Vol 6 (6) ◽  
pp. 561-564 ◽  
Author(s):  
M. Herson ◽  
J.S. Bell ◽  
E.C.K. Tan ◽  
T. Emery ◽  
L. Robson ◽  
...  
Keyword(s):  
Long Term Care ◽  
Medication Regimen ◽  
Term Care ◽  
Factors Associated ◽  
Medication Regimen Complexity ◽  
Regimen Complexity ◽  
Care Facilities

scholarly journals Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibody in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study

2021 ◽  
Author(s):  
Maria Krutikov ◽  
Tom Palmer ◽  
Gokhan Tut ◽  
Christopher Fuller ◽  
Borscha Azmi ◽  
...  
Keyword(s):  
Cohort Study ◽  
Cumulative Incidence ◽  
Prospective Cohort ◽  
Long Term Care ◽  
Natural Infection ◽  
First Year ◽  
Term Care ◽  
Care Facilities ◽  
Prior Infection

Background Long Term Care Facilities (LTCF) have reported high SARS-CoV-2 infection rates and related mortality, but the proportion infected amongst survivors and duration of the antibody response to natural infection is unknown. We determined the prevalence and stability of nucleocapsid antibodies - the standard assay for detection of prior infection - in staff and residents from 201 LTCFs. Methods Prospective cohort study of residents aged >65 years and staff of LTCFs in England (11 June 2020-7 May 2021). Serial blood samples were tested for IgG antibodies against SARS-CoV-2 nucleocapsid protein. Prevalence and cumulative incidence of antibody-positivity were weighted to the LTCF population. Cumulative incidence of sero-reversion was estimated from Kaplan-Meier curves. Results 9488 samples were included, 8636 (91%) of which could be individually-linked to 1434 residents or 3288 staff members. The cumulative incidence of nucleocapsid seropositivity was 35% (95% CI: 30-40%) in residents and 26% (95% CI: 23-30%) in staff over 11 months. The incidence rate of loss of antibodies (sero-reversion) was 2.1 per 1000 person-days at risk, and median time to reversion was around 8 months. Interpretation At least one-quarter of staff and one-third of surviving residents were infected during the first two pandemic waves. Nucleocapsid-specific antibodies often become undetectable within the first year following infection which is likely to lead to marked underestimation of the true proportion of those with prior infection. Since natural infection may act to boost vaccine responses, better assays to identify natural infection should be developed. Funding UK Government Department of Health and Social Care.

Sign in / Sign up

Export Citation Format

Share Document